Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: Trends Cancer. 2022 Feb 3;8(5):404–415. doi: 10.1016/j.trecan.2022.01.008

Figure 3. Clinical translation of transcription targeting therapies in combination with cancer immunotherapies.

Figure 3.

New studies have revealed the immune stimulatory effects of DNA methylation and chromatin regulatory proteins resulting in the use of the DNMT inhibitor decitabine and the HDAC inhibitors entinostat and vorinostat in combination with ICB therapies and CAR-T cells.